 | | Vol. 5.32 – 14 September, 2020 |
| |
|
|
| Using single-cell RNA sequencing and epigenetic profiling, scientists demonstrated that ‘reset’ vascular endothelial cells established an adaptive vascular niche that differentially adjusted and conformed to organoids and tumoroids in a tissue-specific manner.
[Nature] |
|
|
|
 | | PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
| With age, expression of the SARS-CoV-2 receptor angiotensin-converting enzyme 2 was increased in the pulmonary alveolar epithelial barrier, cardiomyocytes, and vascular endothelial cells.
[Cell Research] |
|
|
|
| Researchers report zonation-dependent transcriptomic changes in aged mouse brain endothelial cells (ECs), which prominently implicate altered immune/cytokine signaling in ECs of all vascular segments, and functional changes impacting the blood–brain barrier and glucose/energy metabolism especially in capillary ECs.
[Nature Communications] |
|
|
|
| A transformable dual‐inhibition system based on a self‐assembly peptide was proposed to construct nanofibrous barriers on the cell membrane in situ, which contributed to reducing endothelial permeability and angiogenesis; and inhibiting stemness and metastasis of cancer stem cells in renal cancer.
[Small] |
|
|
|
| The authors generated induced vascular endothelial cells and smooth muscle cells by direct reprogramming of healthy human fibroblasts from donors of different ages and Hutchinson-Gilford Progeria Syndrome patients.
[eLife] |
|
|
|
| Pro-angiogenic G-protein coupled receptor ligands were expressed by patient-derived renal cell carcinomas, and selective inactivation of PI3Kβ reduced patient-derived renal cell carcinomas-stimulated endothelial cells spheroid sprouting.
[Oncogene] |
|
|
|
| Investigators revealed that prostate cancer-associated transcript 6 (PCAT6) boosted triple negative breast cancer cell proliferation, migration, and angiogenesis both in vitro and in vivo.
[Cell Death & Disease] |
|
|
|
| Overexpression of miR-221-3p inhibited endothelial cell proliferation, migration, and cord formation in vitro, while inhibition of miR-221-3p showed the opposite effect.
[Laboratory Investigation] |
|
|
|
| The authors established induced pluripotent stem cells from patients with Shwachman–Diamond syndrome and analyzed their in vitro hematopoietic and endothelial differentiation potentials.
[Scientific Reports] |
|
|
|
| Scientists measured the binding kinetics for VEGF-A165, -A165b, and -A121 with VEGFR1 and VEGF-R2 using surface plasmon resonance.
[Scientific Reports] |
|
|
|
| THRIL was upregulated in coronary atherosclerotic heart disease (CAD) blood samples and endothelial progenitor cells (EPCs). Knockdown of THRIL in EPCs promoted cell viability, inhibited cell autophagy and further suppressed the development of CAD.
[Molecular Medicine] |
|
|
|
| Human microvascular endothelial cells were cultured for six days in a collagen vitrigel membrane (CVM) chamber with or without human dermal fibroblasts cocultured on the reverse surface of the CVM.
[Journal of Pharmacological and Toxicological Methods] |
|
|
|
|
| Investigators speculate that vascular and myeloid cell aging synergize, via IL-6 signaling, to accelerate atherosclerosis.
[Nature Reviews Cardiology] |
|
|
|
| The authors highlight how tissue repair and cancer share cellular and molecular processes that are regulated in a wound but misregulated in cancer.
[Science Signaling] |
|
|
|
| Combining anti-angiogenic therapy and immune checkpoint inhibitors is a valid therapeutic strategy that can enhance cancer immunity and will further expand the landscape of cancer treatment.
[Experimental and Molecular Medicine] |
|
|
|
|
| To research new treatments for hereditary hemorrhagic telangiectasia – a genetic bleeding disorder in which blood vessels do not form properly – the National Institutes of Health (NIH) has awarded Philippe Marambaud, PhD, professor in the Institute of Molecular Medicine at the Feinstein Institutes for Medical Research, a four-year, $1.675 million grant.
[The Feinstein Institutes] |
|
|
|
| Novartis reported the first interpretable results of the Phase III KITE study, assessing the efficacy and safety of Beovu® 6 mg in diabetic macular edema.
[Novartis AG] |
|
|
|
| REGENXBIO Inc. announced that the first patient has been dosed in the AAVIATE trial, a Phase II trial to evaluate the suprachoroidal delivery of RGX-314 using the SCS Microinjector for the treatment of wet age-related macular degeneration.
[REGENXBIO Inc.] |
|
|
|
|
|
|
|
| | The University of British Columbia – Vancouver, British Columbia, Canada |
|
|
|
| | Miller School of Medicine – Miami, Florida, United States |
|
|
|
| | United Therapeutics – Silver Spring, Maryland, United States |
|
|
|
| | University of California, Davis – Davis, California, United States |
|
|
|
|
Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell News
